Samantha Fisch, MD is a second-year internal medicine resident at the University of California San Francisco.

Dr Fisch on the Incidence of Neutropenia With Sacituzumab Govitecan in Advanced Breast Cancer

"[Findings showed 82.6% of patients] had any-grade neutropenia occur, and approximately 50% had grade 3 or higher neutropenia. Furthermore, we found that approximately 50% of patients needed a dose reduction of sacituzumab govitecan; however, [only 8.7%] of patients ended up being hospitalized for sacituzumab govitecan–induced neutropenia, and also [5.4%] had grade 3/4 neutropenic fever.”

Samantha Fisch, MD, second-year internal medicine resident, University of California San Francisco, discusses findings from a single-center retrospective cohort study evaluating the incidence of neutropenia and growth factor use in patients with hormone receptor (HR)–positive/HER2-negative breast cancer or triple-negative breast cancer (TNBC) receiving sacituzumab govitecan-hziy (Trodelvy).

Fisch explained that the retrospective analysis, which was presented at the 

, featured 92 patients with HR-positive/HER2-negative breast cancer (n = 37) or TNBC (n = 55). Findings showed any-grade neutropenia was observed in 82.6% of all patients (TNBC, 83.7%; HR+/HER2–, 81.0%). Grade 3 or higher neutropenia occurred in 53.3% of all patients (TNBC, 58.2%; HR+/HER2–, 45.9%). Grade 3/4 neutropenic fever was reported in 5.4% of all patients; however, all instances occurred in the TNBC cohort, where the rate was 9.1%. Hospitalization due to sacituzumab govitecan–related neutropenia was required in 8.7% of patients, with a median length of stay of 4.5 days (range, 1-10 days).

Dose delays attributed to neutropenia occurred in 15.2% of all patients, 26.4% of patients with TNBC, and 13.5% of patients with HR-positive/HER2-negative breast cancer. The respective rates of dose reductions due to neutropenia were 14.1%, 14.5%, and 13.5%. Only 2.2% of all patients discontinued treatment due to any toxicity, and all were in the HR-positive/HER2–negative cohort. .

Growth factor support was utilized in 87% of patients, including filgrastim (81.5%), pegfilgrastim (13.0%), and both (7.6%). Primary prophylaxis was more common in the HR-positive arm (54.1%) compared with the TNBC arm, where secondary prophylaxis was more common (49.1%).

Fisch and colleagues noted in the presentation of the data that patients who received primary prophylaxis experienced lower rates of grade 3 or higher neutropenia; however, this difference was statistically significant only in the TNBC cohort.

Videos

Samantha Fisch, MD, discusses rates of neutropenia in patients with advanced breast cancer treated with sacituzumab govitecan.

Samantha Fisch, MD

Articles

Dr Fisch on the Incidence of Neutropenia With Sacituzumab Govitecan in Advanced Breast Cancer